China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has finished the required research for two new generic drugs for eye treatment and submitted application to the State Food and Drug Administration (SFDA) in China to perform clinical trials.
Compound Allantoin Vitamin B-E and Aminoethylsulfonic Acid eye drops are used to cure chronic conjunctivitis, cornea trauma and congestive conjunctiva. Dextran and Glycerol eye drops are used to eliminate dryness, sharp pain, and other irritation of the eye. Currently there are no domestic pharmaceutical companies in China that are able to produce Dextran and Glycerol eye drops. Both eye products represent the latest medical technology available worldwide and the Company believes they have promising market potential.
"We are excited to have made such great progress in our research and look forward to receiving SFDA approval for the production of both of our eye products within two years," commented Mr. Yan-qing Liu, Chairman and CEO of China Sky One Medical. "We are fully committed to increasing our drug portfolio by bringing quality new products into the Chinese market."